Abstract：Objective: To analyze serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI) and cystatin C (CysC) expression levels in patients receiving cardiac valve replacement and explore the predictive value on prognosis. Methods: Totally 192 patients who received cardiac valve replacement in Xuzhou Central Hospital from February 2022 to July 2023 were enrolled in the study. The above patients were classified into 147 cases in the good prognosis group and 45 cases in the poor prognosis group by means of the postoperation Serum NT-proBNP, cTnI and CysC levels were measured in all study subjects after admission. Binary Logistic regression analysis was performed to construct a prediction model with NT-proBNP, cTnI and CysC as variables. The predictive value of postoperation serum NT-proBNP, cTnI and CysC on the prognosis was analyzed by receiver operating characteristic curve (ROC). Results: Compared with the good prognosis group, the levels of serum NT-proBNP, cTnI and CysC in the poor prognosis group were enhanced significantly (P<0.05). Logistic regression analysis suggested that NT-proBNP, cTnI and CysC were independent predictors of poor prognosis in patients with cardiac valve replacement. The prediction model was manifested as logit(P)=-11.269 + 0.005 × NT-proBNP + 9.479 × cTnI + 1.508 CysC. ROC curve indicated that the area under the curve (AUC), sensitivity and specificity of combination of NT-proBNP, cTnI and CysC in predicting the poor prognosis were 0.880, 75.56% and 83.67%. The efficiency of combined prediction was better than that of each indicator alone (P<0.05). Conclusion: Serum levels of NT-proBNP, cTnI and CysC in patients receiving cardiac valve replacement are closely related to the prognosis. Postoperation determination of NT-proBNP, cTnI and CysC can provide auxiliary reference value for the prognosis prediction in patients with cardiac valve replacement, so as to guide clinical active prevention and treatment measures.
2025, Vol. 31 
冀公网安备13080202000786号